ETH-LAD
N⁶-ethyl-6-norlysergic acid diethylamide
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
ETH-LAD (N⁶-ethyl-6-norlysergic acid diethylamide) is a semi-synthetic psychedelic of the lysergamide class. It is the N⁶-ethyl structural analog of LSD, with roughly twice the potency per microgram.[1] It activates serotonin receptors in the brain, producing the visual, tactile, and cognitive shifts characteristic of classical psychedelics.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, AL-LAD, 1P-LSD, DMT, 2C-B show less
ETH-LAD was first synthesized in 1976, then pharmacologically established in 1985 as among the most potent lysergamides known.[1] It remained a laboratory curiosity until the 2010s, when it appeared on research chemical markets alongside AL-LAD and other LSD analogs.[4] It is explicitly controlled in the United Kingdom, Germany, and Switzerland; most other jurisdictions leave it unscheduled.
Subjective effects include mild geometric visuals, tactile richness, cognitive clarity, emotional warmth, and appetite enhancement.[5] The experience is gentler and clearer than LSD — warmth and lucidity in place of the overwhelming perceptual intensity typical of higher-dose lysergamide experiences. Nausea, muscle tension, and heavy body load are common at higher doses, and the dose-response curve becomes sharply unpredictable.
ETH-LAD does not produce physical dependence, and no fatalities or organ damage have been reported.[2] The primary risks are psychological — anxiety and panic that scale with dose, compounded by a nonlinear dose-response curve; combining it with serotonin-elevating drugs risks a dangerous overheating response.[6] Published human data are almost entirely absent — current understanding rests on a single 1985 animal study, Shulgin's self-reports, and community experience.
History[edit]
Discovery
ETH-LAD was first synthesized in 1976 by Niwaguchi, Nakahara, and Ishii.[7] It went uncharacterized until 1985, when Hoffman and Nichols established that ETH-LAD and the related AL-LAD were among the most potent lysergamides tested — 1.6–2.3× more potent than LSD in animal models.[1]
Human documentation
Alexander Shulgin published the first human account in TiHKAL: The Continuation (1997).[5] He described it as gentler than LSD, with maintained clarity, warmth, appetite enhancement, and diuretic effects — properties unusual among lysergamides. He also flagged troubling potency loss in stored solutions, even under ideal conditions.
Novel psychoactive substance era
ETH-LAD appeared on research chemical markets in the 2010s,[8] part of a wave that included AL-LAD and other LSD analogs. Brandt et al. provided the first forensic characterization in 2017, noting the compound's market presence had outpaced identification capabilities.[4] Survey data from 2016 found significant user populations in the UK and US, who rated LSD analogs as producing weaker effects and lower perceived risk than LSD.[9]
The name ETH-LAD derives from the N⁶-ethyl substitution on the Lysergic Acid Diethylamide scaffold — a systematic naming convention shared by other lysergamide analogs like AL-LAD (N⁶-allyl) and PRO-LAD (N⁶-propyl). The compound occupies a minor but persistent niche among psychedelic research chemical communities, valued for its reported cognitive clarity and gentler character, though its reputation for batch-to-batch inconsistency and storage instability has limited wider adoption.
Chemistry[edit]
ETH-LAD belongs to the lysergamide family — the same class as LSD, AL-LAD, and 1P-LSD — with the molecular formula C₂₁H₂₇N₃O. The only structural difference from LSD is a single extra carbon at one nitrogen: an ethyl group where LSD has a methyl group, a change that roughly doubles its potency.[1]
A derivative, 1P-ETH-LAD, converts to ETH-LAD in the body, functioning as a prodrug.[4][10] One identification caution: a constitutional isomer called EIPLA shares the same molecular formula and mass, making the two compounds indistinguishable by standard reagent tests — laboratory analysis is required.[11]
Pharmacology[edit]
Mechanism of action
ETH-LAD works primarily by activating serotonin receptors in the brain.[2][3] A drug that blocks those same receptors shuts down the psychedelic experience entirely.[12] Once ETH-LAD binds, a molecular flap closes over it, locking it in place — which is why effects last far longer than the drug persists in the blood.[13]
Pharmacokinetics
No human pharmacokinetic data exist for ETH-LAD. By analogy with LSD, plasma levels peak around 2 hours after ingestion, with a half-life of roughly 2.4 hours.[12][14] ETH-LAD's reported oral duration of 8–12 hours[5] aligns with this pattern — the receptor-locking mechanism extends effects well beyond when blood levels fall.[13]
Metabolism
ETH-LAD is processed by liver enzymes CYP1A2 and CYP3A4.[15] At typical doses, the compound and its metabolites do not appear on standard urine drug tests. A derivative, 1P-ETH-LAD, converts to ETH-LAD in the body,[4][10] functioning as a prodrug — the same relationship that exists between 1P-LSD and LSD.
Neuroscience[edit]
Where it acts
No neuroimaging data exist for ETH-LAD. By class analogy, it likely disrupts the brain's sensory filtering system: activating serotonin receptors in the prefrontal cortex[2][3] reduces the thalamus's gating function, allowing a broader stream of sensory information into conscious processing — the proposed basis for perceptual intensification and novel associations.
Why it matters
One influential model proposes that psychedelics loosen the brain's grip on its habitual interpretations, allowing raw sensory signals to override learned patterns.[16] This accounts for the visual distortions, heightened pattern recognition, and conceptual loosening typical of ETH-LAD. Psychedelics also promote structural changes in brain connections downstream of serotonin activation;[2] whether ETH-LAD's higher potency translates to greater structural change is unknown.
- Does the N⁶-ethyl substitution alter how long ETH-LAD remains bound at the serotonin receptor compared to LSD, and does this explain qualitative differences in the experience?
- What underlies the reported milder visual profile and enhanced tactile and cognitive character compared to LSD?
- Does ETH-LAD promote brain plasticity to a comparable degree as LSD at equivalent doses?
Subjective Effects[edit]
ETH-LAD produces an experience frequently described as clear-headed and warm. The emphasis falls on tactile richness and cognitive lucidity rather than dramatic visual distortions — a character that distinguishes it from most lysergamides.[5] At higher amounts, that gentleness gives way abruptly to a heavier, less predictable experience.
Compared to LSD, ETH-LAD delivers similar duration but reportedly milder visual intensity and less psychological pressure at equivalent effect levels.[9] Shulgin described it as uniquely warm and clear among lysergamides, with unusual properties like appetite enhancement rarely seen in the class.[5]
Effect Grid
At common doses (~60–100 µg oral), the full psychedelic experience emerges: pronounced visual effects including visual drifting, environmental patterning, color shifting, and enhanced closed-eye imagery. Introspection enhancement and thought connectivity increase substantially. Emotional responses deepen — music, nature, and interpersonal interactions take on heightened significance. Cognitive euphoria and a sense of warmth and humor are characteristic.
Physically, stimulation is moderate. Increased appetite and diuretic effects are commonly reported. Some users note mild nausea or muscle tension, though the body load is generally described as manageable at this range. The experience lasts 8–10 hours; sleep is unlikely for at least 8 hours after ingestion.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Symmetrical texture repetition · Environmental patterning · Music enhancement · Brightness alteration · Visual breathing · Visual morphing · Depth perception distortion · Visual diffraction · After-images · Auditory enhancement · Light sensitivity · Perspective distortion · Sound sensitivity · Visual haze / noise · Holotropic state · Auditory distortion · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Visual melting · Visual acuity enhancement · Synesthesia · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual processing acceleration · Visual acuity suppression · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · External hallucinations · Object activation · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Gustatory hallucination · Olfactory hallucination · Persisting hallucinations
Visual breathing · Visual morphing · Depth perception distortion · Visual diffraction · After-images · Auditory enhancement · Light sensitivity · Perspective distortion · Sound sensitivity · Visual haze / noise · Holotropic state · Auditory distortion · Peripheral vision distortion · Spatial disorientation · Touch enhancement · Visual melting · Visual acuity enhancement · Synesthesia · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual processing acceleration · Visual acuity suppression · Touch suppression · Flashbacks · Object transformations · Internal hallucinations · Visual recursion · External hallucinations · Object activation · Environmental orbism / cubism · Visual scenery slicing · Auditory hallucinations · Perspective hallucinations · Gustatory hallucination · Olfactory hallucination · Persisting hallucinations
Wakefulness · Body high · Insomnia · Spontaneous body sensations · Appetite suppression · Muscle tension · Tingling / electric sensations · Temperature dysregulation · Bodily heaviness · Dry mouth · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Vibrations / buzzing · Bodily pressures · Nausea · Dehydration sensation · Excessive sweating · Body schema distortion · Headache · Breathing alteration · Dizziness · Motor control impairment · Tactile euphoria · Trembling · Yawning · Involuntary body movements · Nystagmus (eye wobbles) · Increased urination · Watery eyes · Bruxism · Motor control enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation
Spontaneous body sensations · Appetite suppression · Muscle tension · Tingling / electric sensations · Bodily heaviness · Dry mouth · Heart rate perception changes · Laughter fits · Physical fatigue · Restlessness · Vibrations / buzzing · Bodily pressures · Nausea · Dehydration sensation · Excessive sweating · Body schema distortion · Headache · Breathing alteration · Dizziness · Motor control impairment · Tactile euphoria · Trembling · Yawning · Involuntary body movements · Nystagmus (eye wobbles) · Increased urination · Watery eyes · Bruxism · Motor control enhancement · Vomiting · Seizure threshold reduction · Bodily dissociation
Thought connectivity · Aesthetic enhancement · Openness enhancement · Thought acceleration · Cognitive euphoria · Introspection enhancement · Multiple thought streams · Immersion enhancement · Cognitive flexibility · Creativity enhancement · Cognitive fatigue · Increased nature relatedness · Humor enhancement · Memory suppression · Confusion · Thought loops · Analysis enhancement · Analysis suppression · Cognitive impairment · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Information processing enhancement · Language suppression · Thought organization · Focus enhancement · Cognitive dysphoria · Amnesia
Thought acceleration · Cognitive euphoria · Introspection enhancement · Multiple thought streams · Immersion enhancement · Cognitive flexibility · Creativity enhancement · Cognitive fatigue · Increased nature relatedness · Humor enhancement · Memory suppression · Confusion · Thought loops · Analysis enhancement · Analysis suppression · Cognitive impairment · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Information processing enhancement · Language suppression · Thought organization · Focus enhancement · Cognitive dysphoria
Anxiety · Empathy enhancement · Catharsis · Dysphoria
Trust enhancement · Communication enhancement · Flow state · Sociability enhancement · Communication suppression · Depersonalization · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration
Communication suppression · Depersonalization · Social disconnection · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration
Time cessation
Transpersonal visions · Entity contact
Recursive awareness
Timeline
First alerts emerge as a subtle shift in perception — mild brightening of colors, gentle body awareness, and a faint cognitive sharpening. Easily dismissed as placebo at this stage.
Effects build steadily: visual enhancement becomes unmistakable, emotional tone shifts, and mild physical stimulation develops. Nausea may appear transiently. The characteristic warmth and gentle quality become apparent.
Maximum visual, cognitive, and emotional intensity. Visual drifting, environmental patterning, and enhanced closed-eye imagery are prominent. Cognitive clarity is typically maintained.
Intensity diminishes gradually from peak levels. Visual effects soften, emotional depth remains, and a reflective, contemplative quality predominates. Physical body load, if present, begins to ease.
Residual visual enhancement and mood elevation taper. Cognitive function returns toward baseline. The warm, allowing character may persist as effects fade.
Subtle mood elevation and perceptual freshness may persist for hours to a day. Shulgin described a clean aftermath with no reported next-day effects. Some residual impairment is possible.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No toxicity data exist for ETH-LAD — no LD₅₀ studies, no case reports of organ damage, no fatalities. By analogy with LSD, the therapeutic index is presumed to be extremely wide, but this remains unverified.citation needed
Heart and circulation
LSD-class compounds produce mild, transient increases in heart rate and blood pressure.[12][17] No ETH-LAD-specific cardiovascular data exist, but effects are expected to be clinically insignificant in healthy individuals at typical doses.
Temperature dysregulation
Anecdotal reports describe ETH-LAD as producing more pronounced temperature fluctuations than LSD, particularly at higher doses.citation needed No published data confirm or refute this.
Body load
Community reports describe heavier physical discomfort than LSD at high doses — more nausea, muscle tension, and general unease — with a notably unpredictable dose-response curve.citation needed No published study has verified this.
Psychological risks
- Acute anxiety and panic: Dose-dependent, worsened by unfavorable set and setting. Can escalate to severe distress at high doses.
- Psychosis precipitation: serotonergic psychedelics can trigger or worsen psychotic episodes in individuals with a personal or family history of psychotic disorders.[2]
- Hallucinogen Persisting Perception Disorder (HPPD): Persistent visual disturbances — visual haze / noise, trailing images, halos — occur in over 30% of naturalistic psychedelic users in survey data, though cases that are both persistent and distressing are rare.citation needed No ETH-LAD-specific cases have been reported.
Tolerance and dependence
ETH-LAD is not habit-forming. Classical psychedelics do not produce physical dependence.[2] Tolerance builds rapidly through downregulation within 24 hours of a single dose,[6] with a tolerance half-life of approximately 6 days and full reset at approximately 14 days.inferred
Complete cross-tolerance exists with other serotonergic psychedelics. ETH-LAD would be expected to show full cross-tolerance with LSD and partial cross-tolerance with psilocybin.[6]
Drug interactions
No ETH-LAD-specific interaction data exist. All assessments are based on class pharmacology.
Serotonergic combinations
Combining ETH-LAD with drugs that raise serotonin levels risks serotonin syndrome — a potentially life-threatening condition involving dangerously high body temperature, muscle rigidity, and altered mental status.
- Tramadol: Raises serotonergic load and lowers the seizure threshold. Classified as dangerous by class reasoning.safety citation needed
- MAOIs: Dramatically amplify serotonergic effects. Risk of serotonin syndrome is substantially elevated.safety citation needed
- SSRIs/SNRIs: Long-term use may blunt psychedelic effects through receptor downregulation. Acute interaction dynamics are poorly characterized.inferred
Lithium
Combined use of lithium with LSD has been linked to seizures.safety citation needed This applies to ETH-LAD by class inference.
Cannabis
Cannabis can unpredictably intensify psychedelic effects, increase anxiety, and heighten dissociative elements. No ETH-LAD-specific data exist.
CYP-mediated interactions
ETH-LAD is metabolized by CYP1A2 and CYP3A4.[15] Strong inhibitors of these enzymes — including fluvoxamine, ketoconazole, ritonavir, and grapefruit juice — could theoretically raise ETH-LAD levels. No clinical data exist to quantify this risk.
Contraindications
All contraindications are inferred from class evidence. No ETH-LAD-specific data exist.
- Personal or family history of psychotic disorders: Absolute contraindication. Serotonergic psychedelics can trigger acute psychosis in predisposed individuals.[2]
- Bipolar disorder: Absolute contraindication. Risk of triggering manic episodes.
- Seizure disorders: Relative contraindication. Lysergamides may lower the seizure threshold.safety citation needed
- Heart conditions: Relative contraindication. Transient increases in heart rate and blood pressure may pose risk.[12]
- Concurrent lithium therapy: Absolute contraindication. Associated with seizures and severe adverse events.safety citation needed
- Concurrent MAOI therapy: Absolute contraindication. Risk of serotonin syndrome.
- Pregnancy: Absolute contraindication. No reproductive safety data exist; ergoline derivatives have uterotonic properties.safety citation needed
Harm Reduction[edit]
Forms & Identification
ETH-LAD is distributed on blotter paper or as a liquid solution — formats visually identical to LSD, other lysergamides, and potentially dangerous compounds like NBOMe-series substances. Reagent testing alone cannot confirm identity. Ehrlich reagent confirms an indole compound is present (ruling out NBOMe-class substitutions), but cannot distinguish ETH-LAD from its constitutional isomer EIPLA or from other lysergamides.[11]
ETH-LAD solutions lose potency over months, even under ideal storage conditions,[5] meaning batch-to-batch consistency may vary significantly. Definitive identification requires laboratory analysis (GC-MS or HPLC).[4]
Guidelines
- Test every batch. Ehrlich reagent confirms an indole compound; a negative result rules out dangerous substitutions. Definitive identification requires laboratory analysis.
- Start low. ETH-LAD is more potent per microgram than LSD, and the dose-response curve is reportedly less predictable at higher ranges. First experiences should begin at the low end of the active range.
- Allow for full duration. Clear 12+ hours with no responsibilities. Sleep may be difficult for several hours after primary effects resolve.
- Eat lightly beforehand. A light meal 2–3 hours before reduces nausea risk without an empty stomach.
- Avoid redosing. Rapid tolerance onset means additional doses within hours are unlikely to deepen the experience and may increase body load and duration unpredictably.
- Prepare for body load. Keep water, comfortable clothing, and temperature regulation options available — blankets and access to fresh air.
- Have a sober sitter — especially for first experiences or higher doses. The sitter should know what the person took, when, and how much.
Set & Setting
Mental state (set) and environment (setting) profoundly shape the outcome with all serotonergic psychedelics. ETH-LAD's reputation for gentleness can lead to underestimating its intensity, particularly at higher doses where the dose-response curve becomes unpredictable.
A familiar, comfortable environment with no obligations for the full duration is strongly recommended. A sober, trusted companion who can provide calm reassurance substantially reduces the risk of panic escalating.
Aftercare & integration. The days following an ETH-LAD experience may include residual emotional sensitivity, altered sleep patterns, and a lingering sense of cognitive openness. These are typical and usually resolve within 48–72 hours.
Journaling or discussing the experience with a trusted person helps process novel insights or emotionally charged material. If disturbing thoughts, persistent anxiety, or perceptual disturbances continue beyond a week, consultation with a mental health professional experienced with psychedelic experiences is advisable. Integration circles and psychedelic-informed therapists are available in many regions.
Recovery & Support
ETH-LAD does not produce physical dependence. Some individuals develop patterns of frequent psychedelic use that interfere with daily functioning. If psychedelic experiences are being used to cope with underlying distress, or if use is escalating despite negative consequences, professional support is appropriate.
Resources include the Fireside Project (psychedelic peer support line), MAPS integration therapist directory, and local mental health services. Harm reduction organizations can provide confidential guidance without judgment.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Seek immediate help if:
- The person expresses intent to harm themselves or others
- Complete disconnection from reality with inability to communicate
- Seizure activity
- Severe chest pain or sustained rapid heart rate
- Dangerously high body temperature (skin hot to the touch, confusion, lack of sweating)
Immediate steps
- 1. Call emergency services if any of the above signs are present.
- 2. Move the person to a quiet, safe environment.
- 3. Speak calmly and reassuringly. Do not restrain unless there is immediate danger of self-harm.
- 4. Do not attempt to argue with or talk down altered perceptions — validate their distress while keeping them safe.
- 5. If the person is unconscious, place them in the recovery position.
What to tell the dispatcher
State the substance name (ETH-LAD, a lysergamide psychedelic), the estimated dose, the time of ingestion, and the symptoms observed. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
ETH-LAD is not scheduled under the 1971 United Nations Convention on Psychotropic Substances, leaving regulation to individual countries.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled via Statutory Instrument 2014 No. 3271, effective January 7, 2015. Scheduled alongside AL-LAD, ALD-52, PRO-LAD, and LSZ. Maximum penalties: life imprisonment for supply; 7 years for possession.[18] |
| Germany | Controlled (NpSG) | Controlled under the Neue-psychoaktive-Stoffe-Gesetz, effective July 18, 2019. Production, import for market placement, administration to another person, and trading are punishable. Possession is not specifically penalized under NpSG.[19] |
| Switzerland | Controlled (Verzeichnis E) | Scheduled under the Betäubungsmittelgesetz, List E, effective December 1, 2015.[20] |
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) likely applies when intended for human consumption, treating it as Schedule I due to structural and pharmacological similarity to LSD. |
| Canada | Not controlled | Not a controlled substance under the Controlled Drugs and Substances Act as of 2025. |
| Australia | Not specifically scheduled | No specific scheduling information found. Likely falls under analogue provisions of relevant drug legislation.citation needed |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice and may be out of date.
references
- [1] ^abcdHoffman A, Nichols DE (1985) Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives — Journal of Medicinal Chemistry doi:10.1021/jm00147a022
- [2]
- [3] ^abcCummins BR, Billac GB, Nichols DE, Nichols CD (2025) 5-HT2A receptors: Pharmacology and functional selectivity — Pharmacological Reviews doi:10.1016/j.pharmr.2025.100059
- [4]
- [5]
- [6] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170